Form 4: Enanta Pharmaceuticals Executive Granted Stock Options

Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, was granted 81,000 stock options on November 27, 2024.

Summary

• Tara Lynn Kieffer, Chief Product Strategy Officer at Enanta Pharmaceuticals, was granted 81,000 stock options on November 27, 2024.
• The options have an exercise price of $8.83 per share.
• The options will vest quarterly over four years from the grant date, meaning they will become exercisable in stages.
• The options expire on November 27, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation across the pharmaceutical industry.
• The vesting schedule of four years is also typical for such grants, aligning with long-term value creation.
• Companies like Gilead Sciences, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, Enanta Pharmaceuticals, Tara Lynn Kieffer, vesting, equity